Regeneron Pharmaceuticals Inc. buy Evercore ISI
Summary
This prediction ended on 25.10.25 with a price of €498.50. Massive losses of -42.02% were the result for the BUY prediction by Evercore_ISI. A total of €2.60 was paid as dividends for this prediction. Evercore_ISI has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 2.399% | 2.399% | -10.766% |
| iShares Core DAX® | 0.734% | -0.964% | 17.910% |
| iShares Nasdaq 100 | -2.686% | -2.409% | 4.267% |
| iShares Nikkei 225® | -2.261% | -4.038% | 10.420% |
| iShares S&P 500 | -1.346% | -1.510% | 1.615% |
Comments by Evercore_ISI for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Stopped prediction by Evercore_ISI for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
16.05.24
16.05.25
17.05.25
Regeneron Pharmaceuticals Inc.
14.05.24
14.05.25
15.05.25

